## Geninax (Oral quinolone antibiotic) 

Sales of Geninax decreased 4.5% to ¥11.7 billion in line with a contraction in the Japanese market for oral quino- lone antibiotics and other factors. In fiscal 2013, the market contracted 3.5% year on year to approximately ¥59.0 bil- lion. Geninax’s share was around 22% (on a value basis), making it the second-largest seller in the market. In Octo- ber 2013, Astellas began selling small Geninax tablets that are easier for patients to take. Astellas will continue work- ing hard to achieve further market penetration through co-promotion with Taisho Toyama Pharmaceutical Co., Ltd. 

## Bonoteo (Treatment for osteoporosis) 

Sales of Bonoteo rose by a strong 32.4% year on year to ¥14.1 billion. The release in September 2011 of a 50 mg tablet to be taken once every four weeks contributed sig- nificantly to this increase in sales. Sales of Bonoteo Tablets 50 mg amounted to ¥13.1 billion. In fiscal 2013, the Japa- nese market for the treatment of osteoporosis shrank 1.2% to around ¥79.0 billion. Bonoteo’s share in this market grew steadily to around 20% (on a value basis). Astellas will continue emphasizing patient convenience as well as the bone fracture prevention effect of Bonoteo 50 mg tablets while aiming to further boost its share in this market. 

## Gonax (Prostate cancer treatment) 

Sales of Gonax were ¥2.5 billion in fiscal 2013. Gonax is a gonadotrophin-releasing hormone (GnRH)-receptor blocker with a subcutaneously injectable formulation in-licensed from Ferring Pharmaceuticals. Gonax was launched in Japan in October 2012. GnRH is a hormone produced by the hypothalamus in the brain and is involved in the pro- duction of the male hormone testosterone through binding to the GnRH-receptors in the pituitary gland. Although testosterone is an important hormone that plays a central role in the maintenance of male function, it also stimulates prostate cancer to grow and spread, which often aggravates symptoms in prostate cancer patients. Gonax competitively inhibits the binding of GnRH to the GnRH-receptors, con- trolling the growth of prostate cancer by suppressing the testosterone production. 

Astellas will continue working hard to achieve further market penetration of Gonax along with XTANDI, which was launched in May 2014. 

## Cimzia (rheumatoid arthritis treatment) 

Sales of Cimzia were ¥3.2 billion in fiscal 2013. Cimzia, a rheumatoid arthritis treatment in-licensed from UCB Pharma, S.A. of Belgium, was launched in March 2013 in Japan. Astellas is co-promoting Cimzia with UCB Japan Co., Ltd. 

## Cimzia has a high affinity for TNF-alpha, which is 

involved in the onset and exacerbation of inflammatory diseases such as rheumatoid arthritis (RA), and selectively inhibits its effects. Cimzia is supplied in the form of a pre- filled syringe to facilitate self-administration by RA patients trained by their healthcare professionals. In addition to offering efficacy and safety, the Cimzia is designed to facili- tate usage by patients themselves. Cimzia is expected to play an important role in improving the symptoms of rheu- matoid arthritis patients, as well as their quality of life and adherence.* Following the approval of long-term prescrip- tions from March 2014, Astellas will work hard to achieve further market penetration of Cimzia. 

In June 2014, an application was filed for an additional indication that will make it possible to administer Cimzia to RA patients without previous treatment with anti-RA drugs. * Refers to proactive participation by patients in deciding on a treatment plan, and receiving treatment according to the decision. 

## Suglat (Type 2 diabetes treatment (selective SGLT2 inhibitor)) 

Suglat is a selective SGLT2 (Sodium-Glucose Co-Transporter 2) inhibitor discovered through a research collaboration with Kotobuki Pharmaceutical Co., Ltd. (“Kotobuki”) and jointly developed by Astellas and Kotobuki. In January 2014, it became the first SGLT2 inhibitor to be approved as a treatment for type 2 diabetes in Japan, and was launched in April 2014. 

SGLTs are membrane proteins that exist on the cell surface and transfer glucose into cells. SGLT2 is one sub- type of SGLTs and plays a key role in the reuptake of glu- cose in the proximal tubule of the kidneys. Suglat reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2. 

In fiscal 2013, the market for oral hypoglycemic agents in Japan was valued at around ¥342.0 billion. Astellas will provide a new type 2 diabetes treatment option through the launch of Suglat, an oral type 2 diabetes treatment based on a novel mechanism of action. In the process, 

